KAISA HEALTH(00876)

Search documents
佳兆业健康(00876):创新产品持续增长,皮肤健康线表现突出
Capital Securities· 2025-08-25 12:39
[Table_Rank] 评级: 增持 王斌 首席分析师 SAC 执证编号:S0110522030002 wangbin3@sczq.com.cn 电话:010-81152644 [市场指数走势(最近 Table_Chart] 1 年) 资料来源: wind -0.2 0.0 0.2 0.4 0.6 0.8 1.0 1.2 24-08 24-09 24-10 24-11 24-12 25-01 25-02 25-03 25-04 25-05 25-06 25-07 25-08 康哲药业 恒生指数 [Table_BaseData] 公司基本数据 [Table_Title] 创新产品持续增长,皮肤健康线表现突出 [Table_ReportDate] 康哲药业(0876.HK)公司简评报告 | 2025.08.25 核心观点 请务必仔细阅读本报告最后部分的重要法律声明 [Table_Authors] [Table_OtherReport] [Table_Summary] 最新收盘价(港元) 13.44 一年内最高/最低价(港元) 14.16/6.71 市盈率(当前) 18.12 市净率(当前) 1.76 总股本(亿 ...
佳兆业健康(00876) - 盈利预报-亏损减少
2025-08-21 11:52
盈利預報-虧損減少 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示,概不對因本公佈全部或任 何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Kaisa Health Group Holdings Limited 876 本公佈乃佳兆業健康集團控股有限公司(「本公司」,連同其附屬公司統稱「本集團」) 根據香港聯合交易所有限公司證券上市規則(「上市規則」)第13.09條及香港法例第 571章證券及期貨條例第XIVA部之內幕消息條文(定義見上市規則)作出。 本公司之董事會(「董事會」)謹此知會本公司股東(「股東」)及潛在投資者,基於對 本集團截至二零二五年六月三十日止六個月(「本期間」)未經審核綜合管理賬目及 董事會現時所得資料作出之初步評估,與截至二零二四年六月三十日止六個月錄 得本公司擁有人應佔虧損約24,000,000港元相比,預期本集團將於本期間錄得本 公司擁有人應佔虧損將減少至介乎9,000,000港元至10,000,000港元。該減少乃主要 由於本期間錄得按公平值計入損益之金融資產變動收益約9,000,000港元所 ...
佳兆业健康(00876.HK)8月18日收盘上涨15.0%,成交130.62万港元
Jin Rong Jie· 2025-08-18 08:25
8月18日,截至港股收盘,恒生指数下跌0.37%,报25176.85点。佳兆业健康(00876.HK)收报0.023港 元/股,上涨15.0%,成交量5747万股,成交额130.62万港元,振幅30.0%。 最近一个月来,佳兆业健康累计涨幅0%,今年来累计跌幅16.67%,跑输恒生指数25.97%的涨幅。 财务数据显示,截至2024年12月31日,佳兆业健康实现营业总收入1.72亿元,同比减少0.28%;归母净 利润-4292.66万元,同比减少720.72%;毛利率44.16%,资产负债率17.6%。 在医疗服务板块,和佳运动康复中心联合全国医疗、体能专家,集专业的康复团队和技术体系、顶尖的仪 器设备、优质的医疗环境于一体的高端康复医学专科门诊部。和佳运动康复中心设有康复医学科、中医 科和骨科;区域划分为诊疗室、治疗室、悬吊室、康复训练区、物理治疗区等。目前在深圳开设有三家 线下康复门诊,分别是:福田文博大厦门诊部、罗湖逸翠大厦门诊部、南山金牛广场门诊部、宝安丽晶国 际诊所。 佳兆业健康以"个性化、高质量"的医疗产品和服务为核心,不断提高服务、创新、整合能力,高效运营、 管理和投资水平。通过"内生式增长,外 ...
佳兆业健康(00876) - 董事会会议通告
2025-08-15 11:21
Kaisa Health Group Holdings Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示概不就因本公佈全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 董事會會議通告 佳兆業健康集團控股有限公司(「本公司」)董事會(「董事會」)謹此宣佈,本公司將 於二零二五年八月二十七日(星期三)舉行董事會會議,藉以(其中包括)考慮及批 准本公司及其附屬公司截至二零二五年六月三十日止六個月之中期業績及其發布, 以及考慮派付中期股息之建議(如適用)。 承董事會命 佳兆業健康集團控股有限公司 主席 郭英成 香港,二零二五年八月十五日 於本公佈刊登日期,董事會成員包括執行董事郭英成先生(主席)、羅軍先生、 劉立好先生、羅婷婷女士、謝斌鴻先生及葉豪達先生;及獨立非執行董事劉彥文 博士、呂愛平博士及李祉瑩女士。 876 ...
佳兆业健康(00876) - 截至二零二五年七月三十一日止之股份发行人的证券变动月报表
2025-08-01 08:37
股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00876 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 160,000,000,000 | HKD | 0.00125 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | | 160,000,000,000 | HKD | | 0.00125 HKD | | 200,000,000 | 本月底法定/註冊股本總額: HKD 200,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 ...
佳兆业健康盘中最低价触及0.014港元,创近一年新低
Jin Rong Jie· 2025-05-29 09:01
佳兆业健康集团控股有限公司旗下的健康板块业务投资、融资、运营、管理,拥有—家香港上市公司(股 票代码:00876HK)和一家主板上市公司(股票代码:000403SZ)。核心业务包括:医药、医疗器械、医疗服 务。 (以上内容为金融界基于公开消息,由程序或算法智能生成,不作为投资建议或交易依据。) 在医药板块,佳兆业健康拥有医药稀缺牌照,重点发展高端生物制药、深耕精神麻醉用药。青海制药厂成 立于1958年5月,是国家定点生产麻醉药品的第—个专业厂家。青海制药厂原料药包括阿片粉、吗啡、可 待因、罄粟碱等,其中吗啡系类、那可丁、双氢可待因原料药为国内独家供应。2019年5月,佳兆业集团收 购其54.84%股权,成为青海制药厂大股东。双林生物是在深交所上市的血制品企业,2017年,佳兆业通过协 议转让方式,收购原大股东振兴集团持有的股权,目前佳兆业持有双林生物4.8%股权,为第三股东。 本文源自:金融界 在医疗器械板块,"美加"是国内第一家齿科器械上市公司,是国内规模最大的专业齿科器械、高值耗材供 应商,打造了高科技数字美牙品牌,整合了全球领先的微创牙科美容修复理念、3D打印前沿高科技技术, 以"不磨牙,不伤原牙,轻松 ...
佳兆业健康(00876) - 2024 - 年度财报
2025-04-28 11:00
Financial Performance - The company recorded revenue of approximately HKD 185,400,000 for the fiscal year ending December 31, 2024, a slight decrease of 0.3% compared to HKD 185,900,000 in the previous year[5]. - The company reported a loss attributable to shareholders of approximately HKD 46,400,000 for the fiscal year, compared to a profit of HKD 7,500,000 in the previous year[5]. - Basic loss per share for the fiscal year was HKD 0.92, compared to basic earnings per share of HKD 0.15 in the previous year[5]. - Total revenue for the year was approximately HKD 185,400,000, a slight decrease of about HKD 500,000 or 0.3% from HKD 185,900,000 in the previous fiscal year, primarily due to a decline in average selling prices[18]. - Gross profit for the year was HKD 81,900,000, an increase of approximately HKD 800,000 or 1.0% compared to HKD 81,100,000 in the previous year, driven by an increase in gross profit from the health business[19]. - Gross margin increased to 44.2% from 43.6% in the previous year, reflecting improved production and management efficiency[19]. - The board does not recommend the payment of a final dividend for the fiscal year[14]. - The company reported a retained earnings deficit of HKD 762.8 million, with only HKD 24.9 million in contributed surplus available for distribution[194]. Business Segments - The dental business has maintained stable revenue growth despite challenges, with significant growth in the implant business following the completion of acquisitions and integration[6]. - Revenue from dental business for the year ended December 31, 2024, was approximately HKD 179,000,000, a decrease of about HKD 400,000 or 0.2% compared to HKD 179,400,000 for the year ended December 31, 2023[15]. - The sports rehabilitation outpatient business achieved significant growth, with a compound annual growth rate of 38.3% over the past three years[9]. - The company aims to enhance its brand influence and expand local market share through strengthened insurance partnerships in the sports rehabilitation sector[9]. - The company plans to expand its dental product offerings and sales networks both domestically and internationally, including the U.S. market[7]. Investments and Expansion - The company is investing in a dental implant production facility in Chengdu, expected to commence operations in 2025[6]. - The company plans to invest in a new implant production facility in Chengdu, expected to commence production in 2025[16]. - The group aims to enhance shareholder value by expanding its dental and health businesses, leveraging advanced technology and high-quality medical resources[40]. - The group plans to expand its sales network both domestically and internationally, particularly in the U.S., and develop high-end dental products[41]. Corporate Governance - The board of directors emphasizes the importance of effective corporate governance for maintaining and enhancing shareholder value and investor confidence[55]. - The company has complied with the corporate governance code, except for the absence of an internal audit function, which is reviewed annually[55]. - The board consists of executive directors including the chairman and CEO, and independent non-executive directors, ensuring a balance of skills and experience[60]. - The company has established a nomination committee to review the appointment of new directors and related matters[66]. - The chairman is responsible for setting the overall corporate development direction and business strategy[63]. - The CEO is responsible for the daily management and execution of approved strategies[64]. - The company has a policy for the diversity of board members during the nomination process[62]. - Independent non-executive directors confirm their independence annually according to the listing rules[61]. Risk Management and Internal Controls - The group has established a risk management committee to identify, assess, and manage significant risks, including the evaluation of development projects[91]. - The internal control review indicated that the internal control system is effective and sufficient, with no unresolved major concerns identified by the board[93]. - The board will review the group's performance at least semi-annually to determine the appropriateness of declaring dividends[97]. - An independent international consulting firm has been engaged to conduct an internal control review, covering all significant monitoring areas including financial, operational, and compliance controls[92]. Environmental, Social, and Governance (ESG) - The environmental, social, and governance (ESG) report covers the group's performance in these areas, with over 90% of total revenue generated from its largest subsidiaries[108]. - The board has approved the ESG report, which will transition to a new reporting code starting January 1, 2025[109]. - The group aims to manage its environmental and social impacts actively while fulfilling its responsibilities to enhance sustainability and transparency[113]. - The group is committed to corporate social responsibility, including energy-saving measures and providing a safe and healthy work environment[114]. - The group has identified 21 key ESG issues based on their importance to stakeholders and business operations[121]. Employee Relations and Training - The company has established a fair treatment policy to promote equality among employees regardless of various protected statuses[143]. - The company encourages employee feedback through established upward communication channels, ensuring transparency in handling opinions and complaints[144]. - The company conducted employee training programs, with 78.9% of male employees and 73.2% of female employees receiving training in 2024[153]. - As of December 31, 2024, the company has 861 employees with an overall employee turnover rate of approximately 67.7%[146]. - The turnover rate for male employees is 79.3% in 2024, down from 89.5% in 2023, while female employees have a turnover rate of 56.6%, down from 63.6%[146]. Product Quality and Safety - The company received a total of 124 product complaints during the reporting period, resulting in a complaint rate of 0.026%[161]. - The company has implemented a series of quality control measures to ensure product safety and compliance with standards throughout the production process[162]. - There were no product recalls due to health and safety reasons during the reporting period[162]. - The company has a dedicated quality control department that conducts inspections throughout the production process and before the shipment of finished products[162]. Leadership Changes - Mr. Wu Tianyu will resign as an executive director at the conclusion of the 2024 Annual General Meeting, effective June 14, 2024[197]. - Mr. Zhang Huagang will also resign as an executive director at the conclusion of the 2024 Annual General Meeting[197]. - Four new executive directors have been appointed, effective October 22, 2024[197].
佳兆业健康(00876) - 2024 - 年度业绩
2025-03-24 14:42
Financial Performance - Total revenue for the fiscal year 2024 was HKD 185,357,000, a slight decrease of 0.3% compared to HKD 185,882,000 in fiscal year 2023[3] - Gross profit increased to HKD 81,858,000, up 1.0% from HKD 81,073,000 in the previous year[3] - The company reported a net loss of HKD 50,600,000 for the fiscal year 2024, compared to a profit of HKD 6,150,000 in fiscal year 2023[4] - Basic and diluted loss per share for fiscal year 2024 was HKD 0.92, compared to earnings of HKD 0.15 per share in fiscal year 2023[4] - The loss attributable to equity holders for the year ended December 31, 2024, was HKD 46,355,000, compared to a profit of HKD 7,468,000 for the year ended December 31, 2023[52] - The company recorded revenue of approximately HKD 185,400,000 for the year, a slight decrease of 0.3% compared to HKD 185,900,000 in the previous fiscal year[83] - The loss attributable to equity holders for the year was approximately HKD 46,400,000, compared to a profit of HKD 7,500,000 in the previous fiscal year[83] - The basic loss per share for the year was HKD 0.92, compared to a basic earnings per share of HKD 0.15 in the previous fiscal year[83] Revenue Breakdown - For the year ended December 31, 2023, the revenue generated from external customers in the dental business was HKD 179,441,000, while the health business generated HKD 6,441,000, totaling HKD 185,882,000[24] - For the year ended December 31, 2024, the revenue from external customers in the dental business is projected to be HKD 178,981,000, and the health business is expected to generate HKD 6,376,000, totaling HKD 185,357,000[26] - Revenue from the dental business was approximately HKD 179,000,000, a decrease of about HKD 400,000 from HKD 179,400,000 in the previous fiscal year, primarily due to price reductions influenced by national procurement policies[85] - The total revenue for the dental business in 2024 was HKD 178,981,000, slightly down from HKD 179,441,000 in 2023, reflecting a decrease of approximately 0.3%[37] - The total revenue for the health business in 2024 was HKD 6,376,000, down from HKD 6,441,000 in 2023, a decline of about 1.0%[37] Expenses and Costs - Research and development expenses decreased to HKD 12,477,000 from HKD 16,835,000, reflecting a reduction of 26.5%[3] - Employee costs, including director remuneration, decreased to HKD 113,789,000 in 2024 from HKD 119,605,000 in 2023, a decline of about 4.9%[43] - Administrative expenses decreased by 20.6% to approximately HKD 46,000,000 from HKD 57,900,000 in the previous fiscal year, mainly due to reduced operational projects and professional service fees[92] - Total other income decreased to HKD 5,162,000 in 2024 from HKD 6,748,000 in 2023, a reduction of approximately 23.5%[41] - Capital expenditures for the dental segment were approximately HKD 6,943,000 in 2024, down from HKD 8,487,000 in 2023, a decrease of about 18.2%[30] Assets and Liabilities - Total assets decreased to HKD 312,048,000 from HKD 355,421,000, a decline of 12.2%[6] - The company's net asset value fell to HKD 426,491,000 from HKD 491,764,000, representing a decrease of 13.3%[8] - The total reportable segment assets as of December 31, 2024, decreased to HKD 515,802,000 from HKD 603,461,000 as of December 31, 2023, representing a decline of approximately 14.5%[29] - The reportable segment liabilities as of December 31, 2024, decreased to HKD 74,695,000 from HKD 91,798,000 as of December 31, 2023, indicating a reduction of about 18.6%[29] Impairment and Receivables - The company recorded a significant increase in impairment losses on other receivables, which rose to HKD 21,893,000 from HKD 4,117,000[3] - The group recorded a significant increase in the impairment of other receivables, rising from HKD 7,817,000 in 2023 to HKD 28,992,000 in 2024[70] - The impairment of trade receivables decreased from HKD 2,413,000 in 2023 to HKD 1,372,000 in 2024, a reduction of approximately 43%[67] - Trade receivables increased from HKD 103,306,000 in 2023 to HKD 112,573,000 in 2024, representing an increase of about 9%[66] Taxation - The tax expense for the year ended December 31, 2024, was HKD 1,919,000, compared to a tax credit of HKD 104,000 for the year ended December 31, 2023[50] - The tax impact of non-deductible expenses was HKD 10,559,000 for the year ended December 31, 2024, compared to HKD 27,505,000 for the year ended December 31, 2023[50] - The applicable corporate income tax rate for subsidiaries in China is 25%, with a subsidiary qualifying for a reduced rate of 15% from 2024 to 2026 as a "high-tech enterprise"[48] Governance and Compliance - The company has complied with the corporate governance code, except for the absence of an internal audit function, which is reviewed annually by an independent auditing firm[119] - The audit committee, consisting of three independent non-executive directors, has reviewed the internal controls, risk management systems, and the company's annual performance[120] - The financial statements for the year ending December 31, 2024, have been verified by the auditing firm, ensuring consistency with the audited financial reports[122] - The board of directors includes both executive and independent non-executive members, ensuring a diverse governance structure[125] Future Outlook - The company plans to continue focusing on the development of dental products and rehabilitation services to drive future growth[10] - The group aims to enhance shareholder value by expanding its dental and health business, focusing on high-end dental consumables[113] - The group is currently evaluating the detailed impact of the new Hong Kong Financial Reporting Standard No. 18 on its consolidated financial statements[15] - The company anticipates that the application of the new Hong Kong Financial Reporting Standard No. 18 will affect the presentation of the consolidated income statement and future disclosures, but it is not expected to have a significant impact on the group's consolidated financial position and performance[15]
佳兆业健康(00876) - 2024 - 中期财报
2024-09-26 08:46
Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 88,516,000, a decrease of 4.6% from HKD 92,590,000 in the same period of 2023[4] - Gross profit for the same period was HKD 37,852,000, down from HKD 38,560,000, reflecting a gross margin of approximately 42.7%[4] - The company reported a net loss of HKD 24,264,000 for the six months ended June 30, 2024, compared to a profit of HKD 38,776,000 in the prior year[5] - Total comprehensive loss for the period was HKD 34,247,000, compared to a comprehensive income of HKD 15,058,000 in the same period last year[5] - For the six months ended June 30, 2024, the company reported a segment profit before depreciation and amortization of 3,483 million HKD, compared to 16,355 million HKD for the same period in 2023, indicating a significant decline[19] - The company experienced a segment operating loss of 4,238 million HKD for the six months ended June 30, 2024, compared to a profit of 5,455 million HKD in the prior year, reflecting a negative shift in performance[19] - The company reported a loss attributable to equity holders of HKD 24,264,000 for the six months ended June 30, 2024, compared to a profit of HKD 40,001,000 in the same period of 2023[30] Assets and Liabilities - Non-current assets decreased to HKD 221,886,000 as of June 30, 2024, from HKD 249,646,000 as of December 31, 2023[6] - Current assets totaled HKD 345,834,000, a slight decrease from HKD 355,421,000 at the end of 2023[6] - The company’s total equity as of June 30, 2024, was HKD 457,239,000, down from HKD 491,764,000 at the end of 2023[7] - The company’s total liabilities increased to HKD 511,299 thousand as of June 30, 2024, from HKD 489,548 thousand at the beginning of the period[9] - The company reported total assets of 567,720 million HKD as of June 30, 2024, compared to 605,067 million HKD as of December 31, 2023[21] - Total liabilities amounted to 110,481 million HKD as of June 30, 2024, reflecting a decrease from 113,303 million HKD as of December 31, 2023[20] Cash Flow and Investments - For the six months ended June 30, 2024, the company reported a net cash outflow from operating activities of HKD (26,486) thousand, compared to HKD (1,373) thousand for the same period in 2023[11] - The company generated revenue of HKD 88,516 thousand from external customers, with a pre-tax loss of HKD (22,620) thousand[15] - Cash and cash equivalents decreased by HKD (23,367) thousand during the period, with a cash balance of HKD 147,221 thousand as of June 30, 2024[11] - The company reported a net cash inflow from investing activities of HKD 7,021 thousand, compared to a net outflow of HKD (9,118) thousand in the previous year[11] - The company incurred capital expenditures of HKD (2,120) thousand for the purchase of property, plant, and equipment, down from HKD (9,912) thousand in the previous year[11] Research and Development - Research and development expenses for the six months ended June 30, 2024, were 8,584 million HKD, slightly increasing from 8,522 million HKD in the same period of 2023[27] - The company is expanding its dental implant R&D team, with more sizes of implants entering the final approval stage, expected to receive market approval in the second half of 2024[62] Market and Business Strategy - The company plans to focus on expanding its market presence and enhancing product offerings in the upcoming quarters[4] - The company is actively pursuing new technology developments to improve operational efficiency and product quality[4] - The decline in revenue was primarily due to the Chinese government's centralized procurement price policy, which set price ceilings on domestic dental products[64] - The company is focusing on cost reduction and efficiency measures in its rehabilitation business to adapt to increased competition and market changes[63] - The group aims to enhance shareholder value by expanding its dental and health businesses, focusing on advanced technology and integrating high-quality medical device resources[80] - The dental market in China is expected to maintain rapid growth, with significant development potential due to rising consumer spending and increased awareness of oral health[81] - The group plans to expand its sales network both domestically and internationally, particularly in the U.S., and to develop high-end dental products with cosmetic functions[82] Corporate Governance and Compliance - The company confirmed compliance with the corporate governance code as of June 30, 2024, with no known breaches by employees regarding insider trading guidelines[88] - The company has established written guidelines for employees regarding insider trading, which are at least as stringent as the standard code[86] - The company has maintained compliance with the listing rules and corporate governance standards throughout the reporting period[88] Share Options and Employee Incentives - The company has adopted a share option plan as a long-term incentive for directors and eligible employees, with performance-based compensation policies in place[85] - The company’s share options granted during the period included 50 million options at an exercise price of 0.144 HKD[48] - The stock options granted to key individuals include 40,000,000 for Mr. Luo Jun, 20,000,000 for Mr. Wu Tianyu, and 50,000,000 for Mr. Zhang Huagang, representing approximately 0.79%, 0.40%, and 0.99% of the company's issued share capital respectively[101] - The stock option plan is valid for 10 years from the approval date of June 8, 2015, and is subject to shareholder approval for any amendments[100] Employee and Operational Metrics - As of June 30, 2024, the group had approximately 890 employees in Hong Kong, China, and the United States, a slight decrease from about 893 employees as of December 31, 2023[85] - The average credit period for purchases remained at 90 days, consistent with the previous reporting period[46] Related Party Transactions - The group has engaged in related party transactions, including leasing a property from Kaisa Group Holdings Limited valued at approximately HKD 72,000[104]
佳兆业健康(00876) - 2024 - 中期业绩
2024-08-27 14:48
Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 88,516,000, a decrease of 4.6% from HKD 92,590,000 in the same period of 2023[1] - Gross profit for the same period was HKD 37,852,000, down from HKD 38,560,000, reflecting a slight decline in profitability[1] - The company reported a loss before tax of HKD 22,620,000 compared to a profit of HKD 40,038,000 in the prior year, indicating a significant downturn in financial performance[2] - Total comprehensive loss for the period was HKD 34,247,000, compared to a comprehensive income of HKD 15,058,000 in the previous year[3] - Basic and diluted loss per share for the period was HKD (0.48), compared to earnings per share of HKD 0.79 in the previous year[2] - The loss attributable to equity holders of the company was approximately HKD 24,000,000, compared to a profit of HKD 40,000,000 in the same period of 2023[33] Assets and Liabilities - Non-current assets decreased to HKD 221,886,000 from HKD 249,646,000 as of December 31, 2023, showing a decline in asset value[4] - Current assets totaled HKD 345,834,000, a slight decrease from HKD 355,421,000 at the end of 2023[4] - The company's net asset value decreased to HKD 457,239,000 from HKD 491,764,000, reflecting a reduction in equity[5] - The total assets as of June 30, 2024, amounted to HKD 567,720, with reportable segment assets of HKD 301,334 for the dental business and HKD 243,671 for the health business[13] - The total liabilities were HKD 110,481, with reportable segment liabilities of HKD 72,068 for the dental business and HKD 21,060 for the health business[13] Revenue Segmentation - Revenue from external customers for the dental business was HKD 85,888, while the health business generated HKD 2,628, totaling HKD 88,516 for the six months ended June 30, 2024[10] - Revenue from external customers in China (excluding Hong Kong) was HKD 88,394, compared to HKD 92,256 in the previous year[15] - Revenue from the dental business was approximately HKD 85,900,000, a decrease of about HKD 2,900,000 from HKD 88,800,000 in the same period last year[35] Segment Performance - The company has two operating segments: dental manufacturing and sales, and sports rehabilitation services, indicating a diversified business model[9] - The segment profit before depreciation and amortization for the dental business was HKD 1,894, and for the health business, it was HKD 1,589, resulting in a total of HKD 3,483[10] - The total segment loss before tax was HKD 15,276, with the dental segment reporting a loss of HKD 1,996 and the health segment a loss of HKD 13,280[10] - The company reported a segment profit of HKD 6,803 for the dental business, while the health business incurred a loss of HKD 1,348, leading to a total segment profit of HKD 5,455[11] Research and Development - Research and development expenses amounted to HKD 8,584 for the six months ended June 30, 2024[18] - Research and development expenses amounted to approximately HKD 8,600,000, reflecting the company's commitment to investing in future technologies[36] - The company has applied for a super deduction of 175% on R&D expenses for the taxable profits for the six months ended June 30, 2024, under the new tax policy in China[20] Cash Flow and Investments - The group had a cash balance of approximately HKD 147,200,000 as of June 30, 2024, down from HKD 174,100,000 as of December 31, 2023[44] - Capital expenditures during the period amounted to approximately HKD 2,100,000, primarily invested in production equipment[45] - The company’s investment in limited partnership equity focused on technology and healthcare sectors had a carrying amount of approximately HKD 124,039,000 as of June 30, 2024, down from HKD 144,025,000 as of December 31, 2023[25][26] - The company recorded a fair value loss of approximately HKD 10,681,000 on its investments for the six months ended June 30, 2024, compared to a loss of HKD 28,306,000 for the same period in 2023[25] Market Outlook and Strategy - The dental market in China is expected to maintain rapid growth due to rising consumer spending and increased oral health awareness, with potential for several times the current market size[51] - The company plans to expand its sales network both domestically and internationally, particularly in the U.S., and enhance production capacity in China[51] - The company aims to develop high-end dental products with cosmetic functions and actively participate in national exhibitions to improve service offerings[51] - The implant business is anticipated to achieve significant growth, with more product approvals expected in the second half of 2024[51] - The rehabilitation business will focus on improving product strength and service levels, while exploring regional expansion opportunities[52] Dividend and Taxation - The company did not declare or recommend any dividends for the six months ended June 30, 2024, nor since the reporting date[21] - The company's income tax expense for the six months ended June 30, 2024, was HKD 1,644,000, compared to HKD 1,262,000 for the same period in 2023, reflecting an increase of approximately 30.2%[20]